A. Ianniello

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort

Eleonora Celletti, Myriam Di Penta, Alarico Ariani, Simone Parisi et autres

The efficacy and safety of filgotinib (FIL) for the treatment of patients with rheumatoid arthritis (RA) have been evaluated in a number of randomized controlled trials. However, there is a scarcity of real-world studies evaluating the effectiveness, persistence, tolerability, and safety of …

it, us (code pays fourni par la source)

ABS0436 APREMILAST VS ADALIMUMAB EFFECTIVENESS IN BIOLOGIC-NAIVE PsA

C. Castellani, Olga Addimanda, M. Reta, Mauro Magnani et autres

Background: Both Apremilast (APR) and Adalimumab (ADA) are well known therapeutical strategies for the management of psoriatic arthritis (PsA) [1]. There are no direct effectiveness (i.e. survival rates) comparison between such therapies in biologic-naïve PsA patients. Objectives: To compare APR and ADA …

us, it (code pays fourni par la source)

ABS0668 MULTICENTER OBSERVATIONAL STUDY ON THE EFFICACY OF GUSELKUMAB IN PSORIATIC ARTHRITIS

Alberto Lo Gullo, Silvia Parisi, A. Becciolini, Marino Paroli et autres

Background: Guselkumab (GUS) is an interleukin IL-23 inhibitor which has been proven effective in treating patients with psoriatic arthritis (psA). Objectives: The purpose of this study was to determine the efficacy of GUS to obtain remission or low disease activity (LDA) in …

it, us (code pays fourni par la source)

Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis

Alberto Lo Gullo, Simone Parisi, Andrea Becciolini, Marino Paroli et autres

BACKGROUND: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the …

it, us (code pays fourni par la source)

POS0266 CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY

Alarico Ariani, Federica Lumetti, Simone Parisi, Olga Addimanda et autres

it, us (code pays fourni par la source)

POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS

Maddalena Larosa, Andrea Becciolini, Silvia Parisi, E. DI Donato et autres

it (code pays fourni par la source)

AB0595 DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA

Maddalena Larosa, Dario Camellino, A. Becciolini, E. DI Donato et autres

it (code pays fourni par la source)

AB0302 DISCONTINUATION RATE AND PREDICTORS OF JAKI DISCONTINUATION IN A REAL LIFE COHORT: RESULTS FROM A MULTICENTRIC ITALIAN STUDY ON 864 PATIENTS WITH RA

Maddalena Larosa, Alarico Ariani, Dario Camellino, Andrea Becciolini et autres

it, us (code pays fourni par la source)

AB0386 DIFFERENCES BETWEEN JAKIS-NAIVE AND JAKIS-NOT NAIVE PATIENTS IN A REAL LIFE CLINICAL SETTING: DATA FROM AN PROSPECTIVE MULTICENTRIC ITALIAN STUDY.

Maddalena Larosa, Andrea Becciolini, Elena Bravi, Dario Camellino et autres

it (code pays fourni par la source)

AB0481 UPADICITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: OBSERVATION FROM AN ITALIAN MULTI-CENTRIC COHORT

Palma Scolieri, Vincenzo Bruzzese, Maddalena Larosa, Alberto Farina et autres

it (code pays fourni par la source)

AB0452 SURVIVAL RATE OF BARICITINIB IN A LARGE COHORT OF RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF REAL-WORLD DATA

Simone Parisi, Andrea Becciolini, Maria Chiara Ditto, P. Del Medico et autres

it, ch, us, be, de, gb, fr, mx, cz (code pays fourni par la source)

AB1114 MUSCULOSKELETAL ULTRASOUND BASELINE ASSESSMENT IMPROVES THE RESPONSE TO APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A MULTICENTER STUDY

A. Farina, P. Del Medico, Andrea Becciolini, Federica Lumetti et autres

Background Psoriatic arthritis (PsA) is an inflammatory rheumatic disease characterized by different phenotypes in terms of joint involvement. Apremilast, PDE4 competitive inhibitor, has been introduced in the treatment of adult psoriatic arthritis (PsA) with moderate disease activity. Musculoskeletal ultrasound (MUS) is useful …

it (code pays fourni par la source)